Briacell Therapeutics -CW27BCTXWPreferred / convertible
13F holders, Q2 2024 (June 30)4holders +1
1new positions
0sold out
$0.26avg. 13F price*
At the end of Q2 2024, 4 institutions reported holding Briacell Therapeutics -CW27 (BCTXW) in their 13F filings, up 1 from Q1 2024. 1 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($101K), Redmond Asset Management, LLC ($17K) and UBS Group AG ($3K).
- Company
- Briacell Therapeutics -CW27
- CUSIP
- 10778Y112
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3K |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 10,023 shares bought, net +10,023 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Armistice Capital, LLC | — | No change | 375,000 | $101K |
| Redmond Asset Management, LLC | — | No change | 75,000 | $17K |
| UBS Group AG | — | New | 10,023 | $3K |
| Osaic Holdings, Inc. | — | No change | 800 | $184 |
"% of holder's portfolio" is BCTXW's weight in each manager's 13F, not the share of Briacell Therapeutics -CW27 the manager owns.